

Impact of Smoking on the Complications of Diabetes Mellitus

Dr. Md. Siddiqul Islam¹*, Ferdowsi Akter¹

Abstract

Diabetes is one of the most prevalent metabolic diseases, and it develops as a result of a complex interaction of genetic, environmental, and lifestyle factors. This paper gives an analysis of the effect of smoking on the occurrence of vascular diseases and glycemic control among diabetic patients, as well as the possible role of smoking in diabetes predisposition in good condition. Many types of research (not based on patients with diabetes) have demonstrated the harmful effects of smoking on wellbeing. Various surveys on smoker diabetic patients have unequivocally reported that elevated incidence of smoking and mortality linked to the occurrence of macrovascular complications. Smoking is also linked to the onset of microvascular complications early in life and can play a role in the progression of type 2 diabetes. Previous studies conducted on smoking habit of diabetic patients concluded that smoking is positively correlated with type 2 diabetes onset of macrovascular complications as well as mortality.

Keywords: *Diabetes, T1DM, T2DM, Microvascular, Macrovascular, Smoking.*

Introduction

In case of many chronic diseases like cardiovascular disease (CVD), cancer, chronic obstructive pulmonary disease (COPD), asthma and diabetes, smoking plays a major modifiable predisposing factor. The smoking suspension is one of only a handful few steps which can securely and cost-successfully be suggested for diabetic people. According to the American Diabetes Association's recommendations, stopping smoking is the best steps to avoid diabetes related problems (Haire-Joshu et al., 2004). Numerous investigations have shown that the antagonistic impacts of smoking on diabetes mellitus are identified in both macrovascular and microvascular illnesses (Paul et al., 2016, Martín-Timón et al., 2014, Qin et al., 2013). Despite the fact that smoking decreases body weight, it is related to excess fat in the abdomen (Canoy et al., 2005). Tobacco smoke contains compounds that allow free radicals to develop, destroying homeostasis of blood vessel and the vascular endothelium function (Śliwińska-Mossoń et al., 2015; Śliwińska-Mossoń et al., 2013). Other than disrupting cell function directly, it also enhances inflammation/oxidative stress (Śliwińska-Mossoń et al., 2012) and damage of β -cell function (Milnerowicz et al., 2007). A lot of studies have revealed the relationship between the use of tobacco and diabetes development. However, these studies are comprehensive and complex since components made of tobacco e.g. cigarettes constitutes of 7357 different chemical compounds and 1015 (Śliwińska-Mossoń et al., 2013) to 1017 (Milnerowicz et al., 2007) free radicals, along with other well-known compounds like carbon monoxide, tar, arsenic, lead, and nicotine, (Gordon and Flanagan, 2016; Bizon et al., 2013). All of these lead to different processes that may be responsible in disease development. Additionally, to entangle the circumstances, none of these pathways are totally unrelated or direct, and they all activate a slew of chemical interactions and interconnections between inflammatory and metabolic processes. (Gordon and Flanagan, 2016; Bizon et al., 2013, Śliwińska-Mossoń and Milnerowicz, 2017).

¹. Department of Pharmacy, Southeast University, Dhaka

*Corresponding author: Dr. Md. Siddiqul Islam, Associate Professor and Chairman, Department of Pharmacy, Southeast University, Dhaka

We will focus our study to find out the role of smoking on the occurrence of macro and microvascular diseases along with glycemic control among diabetes affected patients and try to compare them with nonsmoker diabetic patients.

Cigarette Smoking and Vascular Complexity

Macrovascular Complexity

In patients with diabetes, complications of blood vessels like ischaemic heart disease (IHD), stroke, and disease of peripheral arteries are the leading causes of deaths as well as sufferings, with a likelihood of cardiovascular problems up to four times higher than ordinary people (Rawshani et al., 2017). Smoking is one of the main culprits of the cardiovascular disease burden (Roth et al., 2015, Rawshani, 2018). Therefore smoking raises the risk of macrovascular problems in diabetic patients. Several studies have looked into the correlation between obesity, diabetes, and cardiovascular risk. Study of Pan and colleagues (Pan et al., 2015) on the likelihood of overall mortality and adverse events in smoker (regular) diabetic patients found that they have an increased rate of cardiovascular (R=1.44) and coronary heart disease (R=1.51), stroke (R=1.54) and cardiac failure (R=1.43) compared to non-smoker diabetes patients. Not only this, likelihood of the disease of the peripheral artery get two times higher (RR=2.15) in these patients compared to another one. Diabetic patients who quit smoking still showed a higher chance of total mortality (10–20%), mortality related to heart or blood vessel complications, compared with those who never smoke and stroke is the lone exception here. These results confirm the results of previous meta-analysis of 46 studies, which found that patients with diabetes had a greater risk of overall death, cardiovascular outcomes and CHD than people without diabetes (Qin et al., 2013). Furthermore, smokers who have given up smoking have demonstrated a declining pattern (Qin et al., 2013). Recently three new reports have backed up these results. According to a cohort analysis carried out by the Swedish National Diabetes Registry on a large population, smoking was one of five most substantiated mortality and acute myocardial infarction markers among type-2 diabetes patients (Rawshani, 2018). Smoking was linked to a higher rate of all-cause mortality in men (RR=1.71) and women (RR=2.04) in another retrospective study conducted among 132,462 Chinese patients (who used public primary care facilities in 2010) (Wan et al., 2017). A major longitudinal cohort analysis measured the risk of CHD incidence in the third study. Data on all-cause mortality yielded similar findings (Barengo et al., 2017). These results indicated that patients with diabetes who smoke have a greater chance of macrovascular risks than people who do not (Campagna et al., 2019).

Microvascular Complexity

Compared to the number of studies on macrovascular complications, a small number of studies have looked into the connection between cigarette smoking and microvascular complexity including inflammation of nephron, retina, and neuron. Outcome of the tests, especially for T2DM, are not entirely consistent.

Nephropathy

Chronic albuminuria, a slow decrease in glomerular filtration rate (GFR), edema of periphery, and hypertension are all symptoms of diabetic nephropathy. It is regarded as the most severe complication in diabetic patients, and it is thought to be a vital reason for end-stage kidney failure (Harvey, 2003). Smoking appears to increase the risk of nephropathy initiation and progression in people with diabetes, including those with T1DM (Su et al., 2017). A four-year long study conducted among 943 Type-1 diabetes patients with normoalbuminuria at the onset, researchers discovered chronic albu-

minuria in 109 of the 943 participants (Scott et al., 2001). Current smoking, as well as impaired glycemic regulation (HbA1C > 8%), had a significant potentiating effect on the onset of chronic albuminuria. Study of Feodoroff et al. investigated the impact of cigarette smoking on diabetic nephropathy's onset and development in a large number of T1DM patients (Feodoroff et al., 2016). Active smoking was discovered to be a risk factor for development of diabetic nephropathy, with a progression with increasing smoking rate, according to the researchers. Anyone who quit smoking has the same risk of developing and worsening diabetic nephropathy as nonsmokers after multivariable adjustment (Feodoroff et al., 2016). Other researches that attempted to determine the link between smoking and development of nephropathy in type-2 diabetes patients were inconclusive. For e.g., only male patients have a higher chance of having a low GFR (OR=2.20) compared to non-smokers diabetic ones (De Cosmo et al., 2006). In smokers with T2DM, faster development of diabetic nephropathy has been found more often than in non-smoking cases (Chuahirun et al., 2003; Phisitkul et al., 2008). In a study of Taiwanese men, researchers discovered a close dose–response association between cigarette smoking and proteinuria in T2DM men (Hsu et al., 2010). Proteinuria was found to be 2.78 and 3.20 times more common in smokers than nonsmokers. Tobacco use has a significant dose–response impact on the occurrence of proteinuria in all patients, like those with a short history of diabetes, good control of blood pressure, and those who are young. In comparison to nonsmokers, smokers have a faster rate of development of proteinuria from microalbuminuria to eventually end stage renal failure. A current meta-analysis of 20,056 T2DM patients discovered that the odds ratio developing albuminuria among smokers was 2.13 (95 percent CI 1.32, 3.45) compared to non-smokers, with illness period being the only other statistically important risk factor (Kar et al., 2019).

Retinopathy

Among T1DM patients smoking found as a risk factor for developing retinopathy (Gaedt Thorlund et al., 2013.), but in T2DM patients, impact of cigarette smoking is contested, with several reports showing no correlation or even a reduced chance of developing retinopathy in smokers (Stratton et al., 2001, Yun et al., 2016). Cigarette Smoking was not statistically linked with the risk of diabetic retinopathy prevalence or development in the Wisconsin Epidemiologic Study of Diabetic Retinopathy's 4-year and 10-year follow-ups (Moss et al., 1996). In a 6-year follow-up of 1216 patients with T2DM, data from the United Kingdom Prospective Diabetes Study (UKPDS) revealed that retinopathy development (incidence) was not linked with smoking (Stratton et al., 2001). The development of vasculopathy in smokers was substantially slower than in non-smokers among the 703 individuals who had diabetic retinopathy at the start of the trial. This contradictory evidence, that smokers with T1DM have a substantially higher risk of diabetic retinopathy than nonsmokers, whereas smokers with T2DM have a significantly lower risk, was recently verified (Cai et al., 2018).

Neuropathy

Two significant articles have looked at the connection between smoking and the possibility of having diabetic neuropathy. In the European Diabetes Prospective Complications Trial, neuropathy was measured at baseline and after a 7.3-year follow-up discovered that, aside from glycemic control, the prevalence of neuropathy was significantly correlated with smoking (OR=1.68) (Tessfaye et al., 2005). The second study (Clair et al., 2015) looked at the progression of diabetic neuropathy among 5558 patients using a comprehensive analysis of 10 prospective cohorts and 28 cross-sectional researches. 1550 new diabetic neuropathy cases were discovered during a two-to-ten-year period; the risk of neuropathy in smoker's diabetic patients was not substantially higher. A secondary study discovered an important connection between smoking and diabetic

neuropathy in type 1 diabetes (OR=1.74; 7 studies), but not in T2DM patients. (Order of magnitude=0.65; 3 studies) (Clair et al., 2015). These inconsistencies may be due to the low sensitivity of traditional neuropathy diagnostic procedures (Dros et al., 2009). Using more detailed and precise nerve conduction tests, Ahmad and colleagues (Ahmad et al., 2016) found that smoking pose an additional risk for neuropathy symptoms in patients with type-2 diabetes, where heavy smokers show worst outcome. Before other considerations are taken into account, research on smoking and its impact on microvascular complication may appear to show a perplexing relationship. The effect of smoking varies on these situations depending on the type of diabetes, such as T1DM or T2DM, as well as gender. Overall, there are few comprehensive prospective studies available, further analysis is needed, as is so often the case.

Smoking and Glycemic Control

The impact of smoking on glycemic regulation in diabetics has been poorly researched, with sometimes conflicting findings. In patients with diabetes, cigarette smoking worsens insulin tolerance (Anan et al., 2006); hence, stopping smoking should improve glycemic regulation. Smoking abstinence, on the other hand, often leads to worsened glycemic regulation, presumably as a function of the weight gain that happens frequently after quitting (Bush et al., 2016). A Japanese survey of 25 diabetic patients found that those who stopped smoking had worse glycemic control than those who smoked (Lino et al., 2004). In a cohort research of THIN (The Health Improvement Network) including T2DM patients, it was found that stopping smoking imparts bad glycemic control (Taylor et al., 2015). Data of both Fukuoka Diabetes Registry (Kaizu et al., 2014) and the Swedish National Diabetes Registry (Nilsson et al., 2004) indicated that the quantity of cigarettes smoked every day was in proportional with HbA1c level. Despite this, other researches did not found a connection between smoking and blood sugar regulation (Anan et al., 2006). In a separate cohort study including 10,551 Chinese men (OR=1.49) and 15,297 diabetic Chinese women (OR=1.56) smoking was associated with an increased chance of weak blood sugar control (defined as HbA1c>7.0%), particularly in the elderly (Peng et al., 2018). Common confounding variables, such as socio-demographic and lifestyle considerations, have little impact on the partnership. The elevated risk of inadequate glycemic function in smokers relative to nonsmokers was only normalized after at least 10 years of smoking cessation. Another research (Su et al., 2017) on 7763 male T2DM patients in China showed that cigarette smoking contributed to higher levels of plasma glucose in fasting state and HbA1c, particularly in those with the longest smoking history and pack-years. In comparison to nonsmokers, active smokers with a 30-year smoking history increased their HbA1c by 0.27 percent, and smokers with 40 pack-years increased their HbA1c by 0.38 percent. The variations in the sample populations may explain the contradictory findings. Confounding causes, such as established lifestyle risk factors that were not investigated in any of the experiments, may be to blame for the differences (Campagna et al., 2019).

Conclusion

Around 422 million people around the world are suffering from diabetes and a lot of them are smoker. Smoking itself pose a great health risk and when it combines with diabetes mellitus it may bring the worst macro and microvascular complications associated with diabetes mellitus. Though some studies regarding blood sugar control showed that smoking associated with good glycemic control maximum literatures showed opposite figure. Further extensive studies require getting a clear picture of effect of smoking in T1DM and T2DM.

References

- Ahmad A, Moinuddin A, Ahsan A, Goel A. (2016). Study of electrophysiological changes insensory nerves among diabetic smokers. *Journal of Clinical and Diagnostic Research*, 10(1), CC09–11.
- Anan F, Takahashi N, Shinohara T, Nakagawa M, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yonemochi H, Eshima N, Saikawa T, Yoshimatsu H. (2006). Smoking is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. *European Journal of Clinical Investigation*, 36(7):459–65.
- Bizon A, Flanagan P, Antonowicz-Juchniewicz J, et al. (2013). The influence of the intensity of smoking and years of work in the metallurgy on pro-oxidant/antioxidant balance in the blood of smelters. *Toxicology and Industrial Health*, 29(2), 149–161.
- Bush T, Lovejoy JC, Deprey M, Carpenter KM. (2016). The effect of tobacco cessation on weight gain, obesity and diabetes risk. *Obesity (Silver Spring)*, 24(9), 1834–41.
- Cai X, Chen Y, Yang W, Gao X, Han X, Ji L. (2018). The association of smoking and risk of diabetic retinopathy in patients with type 1 and type 2 diabetes: a meta-analysis. *Endocrine*. 62(2), 299–306.
- Campagna D, Alamo A, Di Pino A, Russo C, Calogero AE, Purrello F, Polosa R. (2019). Smoking and diabetes: dangerous liaisons and confusing relationships. *Diabetology & metabolic syndrome*, 11(1), 1-2.
- Canoy D, Wareham N, Luben R, et al. (2005). Cigarette smoking and fat distribution in 21828 British men and women: a population-based study. *Obesity Research & Clinical Practice*, 13(8), 1466–1475.
- Chuahirun T, Khanna A, Kimball K, et al. (2003). Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes. *American Journal of Kidney Diseases*, 41(1), 13–21.
- Clair C, Cohen MJ, Eichler F, Selby KJ, Rigotti NA. (2015). The effect of cigarette smoking on diabetic peripheral neuropathy: a systematic review and meta-analysis. *Journal of General Internal Medicine*, 30(8), 1193–203.
- De Cosmo S, Lamacchia O, Rauseo A, et al. (2006). Cigarette smoking is associated with low glomerular filtration rate in male patients with type 2 diabetes. *Diabetes Care*, 29(11), 2467–70.
- Dros J, Wewerinke A, Bindels PJ, van Weert HC. (2009). Accuracy of monofilament testing to diagnose peripheral neuropathy: a systematic review. *Annals of Family Medicine*, 7(6):555–8.
- Feodoroff M, Harjutsalo V, Forsblom C, Thorn L, Wadén J, Tolonen N, Lithovius R, Groop PH. (2016). Smoking and progression of diabetic nephropathy in patients with type 1 diabetes. *Diabetes Care*, 26(3), 911-916.
- Gaedt Thorlund M, Borg Madsen M, Green A, Sjølie AK, Grauslund J. (2013). Is smoking a risk factor for proliferative diabetic retinopathy in type 1 diabetes. *Ophthalmologica*, 230(1), 50–4.

- Gordon P and Flanagan P. (2016). Smoking: a risk factor for vascular disease. *Journal of Vascular Nursing*, 34(3), 79–86.
- Haire-Joshu D, Glasgow RE and Tibbs TL. (2004). American Diabetes Association. Smoking and diabetes. *Diabetes Care*, 27, S74–S75.
- Harvey JN. (2003). Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. *Current Opinion in Nephrology and Hypertension*, 12(3), 317–22.
- Hsu CC, Hwuang SJ, Chen T, Huang MC, Shin SJ, Wen CP, Shih YT, Yang HJ, Chang CT, Chang CJ, Loh CH, Fuh MT, Li YS, Chang HY. (2010). Cigarette smoking and proteinuria in Taiwanese men with type 2 diabetes mellitus. *Diabetic Medicine*, 27(3), 295–302.
- Kaizu S, Kishimoto H, Iwase M, Fujii H, Ohkuma T, Ide H, Jodai T, Kikuchi Y, Idewaki Y, Hirakawa Y, Nakamura U, Kitazono T. (2014). Impact of leisure- timephysical activity on glycemic control and cardiovascular risk factors inJapanese patients with type 2 diabetes mellitus: the Fukuoka diabetesregistry. *PLoS ONE*, 9, e98768.
- Kar D, Gillies C, Nath M, Khunti K, Davies MJ, Seidu S. (2019). Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. *Acta Diabetologica*, 56(8), 839–50.
- Lino K, Iwase M, Tsutsu N, Iida M. (2004). Smoking cessation and glycaemic control in type 2 diabetic patients. *Diabetes, Obesity and Metabolism*, 6(3), 181–6.
- Martín-Timón I, Sevillano-Collantes C, Segura-GalindoA, et al. (2014). Type 2 diabetes and cardiovascular disease: haveall risk factors the same strength? *World Journal of Diabetes*, 5(4), 444–470.
- Milnerowicz H, Śliwińska-Mossoń M, Rabczyński J, et al. (2007). Dysfunction of the pancreas in healthy smoking persons and patients with chronic pancreatitis. *Pancreas*, 34(1), 46–54.
- Moss SE, Klein R, Klein BE. (1996). Cigarette smoking and ten-year progression of diabetic retinopathy. *Ophthalmology*, 103(9), 1438–42.
- Nilsson PM, Gudbjornsdottir S, Eliasson B, Cederholm J. (2004). Steering Committee of the Swedish National Diabetes Register. Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes: data from the National Diabetes Register in Sweden. *Diabetes & Metabolism*, 30(3), 261–8.
- Pan A, Wang Y, Talaei M, Hu FB. (2015). Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. *Circulation*, 132(19), 1795–804.
- Paul SK, Klein K, Majeed A, et al. (2016). Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetes. *Journal of Diabetes*, 8(3), 354–362.
- Peng K, Chen G, Liu C, et al. (2018). Association between smoking and glycemic control in diabetic patients: results from the Risk Evaluation of cancers in Chinese diabetic Individuals: a longitudinal (REACTION) study. *Journal of Diabetes*, 10(5), 408–18.

- Phisitkul K, Hegazy K, Chuahirun T, Hudson C, Simoni J, Rajab H, Wesson DE. (2008). Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. *The American Journal of the Medical Sciences*, 335(4), 284–91.
- Qin R, Chen T, Lou Q, Yu D. (2013). Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: meta-analysis of observational prospective studies. *International Journal of Cardiology*, 167(2), 342–50.
- Rawshani A, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdóttir S. (2017). Mortality and cardiovascular disease in type 1 and type 2 diabetes. *New England Journal of Medicine*, 376(15), 1407–18.
- Rawshani A. (2018). Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. *The New England Journal of Medicine*, 379(7), 633–644.
- Scott LJ, Warram JH, Hanna LS, Laffel LM, Ryan L, Krolewski AS. (2001). A nonlinear effect of hyperglycemia and current cigarette smoking are the major determinants of the onset of microalbuminuria in type 1 diabetes. *Diabetes*, 50(12), 2842–9.
- Śliwińska-Mossoń M, Milnerowicz H, Jabłonowska M, et al. (2012). The effect of smoking on expression of IL-6 and antioxidants in pancreatic fluids and tissues in patients with chronic pancreatitis. *Pancreatology*, 12(4), 295–304.
- Śliwińska-Mossoń M, Milnerowicz H. (2017). The impact of smoking on the development of diabetes and its complications. *Diabetes and Vascular Disease Research*, 14(4), 265–76.
- Śliwińska-Mossoń M, Milnerowicz S, Nabzdyk S, et al. (2015). The effect of smoking on endothelin-1 in patients with chronic pancreatitis. *Applied Immunohistochemistry and Molecular Morphology*, 23(4), 288–296.
- Śliwińska-Mossoń M, Sciskalska M, Karczewska-Górska P, et al. (2013). The effect of endothelin-1 on pancreatic diseases in patients who smoke. *Advances in Clinical and Experimental Medicine*, 22(5), 745–752.
- Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR. (2001). UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. *Diabetologia*, 44(2), 156–63.
- Su J, Qin Y, Shen C, Gao Y, Pan EC, Pan XQ, Tao R, Zhang YQ, Wu M. (2017). Association between smoking/smoking cessation and glycemic control in male patients with type 2 diabetes. *Zhonghua Liu Xing Bing Xue Za Zhi*. 38(11):1454–9
- Su S, Wang W, Sun T, Ma F, Wang Y, Li J, Xu Z. (2017). Smoking as a risk factor for diabetic nephropathy/a meta analysis. *International Urology and Nephrology*, 49(10), 1801–7.
- Taylor AE, Davies NM, Munafo MR. (2015). Smoking and diabetes: strengthening causal inference. *The Lancet Diabetes & Endocrinology*, 3(6), 395–6.
- Tesfaye S, Chaturvedi N, Eaton SE, et al. (2005). Vascular risk factors and diabetic neuropathy. *The New England Journal of Medicine*, 352(4), 341–50.
- Yan ZP, Ma JX. (2016). Risk factors for diabetic retinopathy in northern Chinese patients

with type 2 diabetes mellitus. *International Journal of Ophthalmology*, 9(8), 1194–9.

Yun JS, Lim TS, Cha SA, Ahn YB, Song KH, Choi JA, Kwon J, Jee D, Cho YK, Park YM, Ko SH. (2016). Clinical course and risk factors of diabetic retinopathy in patients with type 2 diabetes mellitus in Korea. *Diabetes & Metabolism*, 40(6), 482–93.